Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints

Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose.

Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here.

Dosimetry on intraoperative ultrasound (US) of 20 FS and 28 TS patients was compared. The prostate, bladder, urethra and bulbomembranous (BM) urethra were delineated. Toxicity was assessed using the CTCAE version 4. 0. Dose constraints to reduce toxicity in TS patients were evaluated with receiver operating characteristic (ROC) analysis.

FS I-125 BT significantly reduces bladder and urethral dose compared to TS. Grade 3 GU toxicity occurred once in the FS group. For TS patients late severe (⩾grade 3) GU toxicity was frequent (38% in the total 61 patients and 56% in the 27 analyzed patients). TS patients with ⩾grade 3 GU toxicity showed higher bladder D2cc than TS patients without toxicity (median 43Gy) (p=0. 02). The urethral V100 was significantly higher in TS patients with several toxicity profiles: ⩾grade 3 urethral strictures, ⩾grade 2 urinary retention and multiple ⩾grade 2 GU toxicity events. Dose to the BM urethra did not show a relation with stricture formation. ROC-analysis indicated a bladder D2cc

FS I-125 BT reduces urethral and bladder dose significantly compared to TS. With TS, there is an increased risk of cumulative dose and severe GU toxicity. Based on these findings, bladder D2cc should be below 70Gy and urethral V100 below 0. 40cc.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2015 Sep 05 [Epub ahead of print]

Max Peters, Jochem van der Voort van Zyp, Carel Hoekstra, Hendrik Westendorp, Sandrine van de Pol, Marinus Moerland, Metha Maenhout, Rob Kattevilder, Marco van Vulpen

Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands.  Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. , Radiotherapeutic Institute RISO, Deventer, The Netherlands. , Radiotherapeutic Institute RISO, Deventer, The Netherlands. , Radiotherapeutic Institute RISO, Deventer, The Netherlands. , Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. , Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. , Radiotherapeutic Institute RISO, Deventer, The Netherlands. , Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe